Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The Canadian Journal of Cardiology|June 7, 2011
Physiologic evaluation of myocardial bridging: a new analysis for an old diseaseKyungil Park, Tae-Jin Youn, Kyung-Woo Park, et al.
Trials|November 24, 2011
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trialYoung-Rak Cho, Young-Dae Kim, Tae-Ho Park, et al.
Circulation|November 18, 2020
Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS TrialHyo-Soo Kim, Jeehoon Kang, Doyeon Hwang, et al.
ESC Heart Failure|January 18, 2018
The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodellingKyungil Park, Young-Dae Kim, Ki-Sik Kim, et al.
Heart (British Cardiac Society)|November 21, 2015
Physiological and clinical relevance of anomalous right coronary artery originating from left sinus of Valsalva in adultsSang Eun Lee, Cheol Woong Yu, Kyungil Park, et al.
JACC. Asia|March 6, 2023
Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal FunctionJun Pil Yun, Jeehoon Kang, Kyung Woo Park, et al.
Eclinicalmedicine|January 9, 2026
Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with ultrathin-strut drug-eluting stents in South Korea: 3-year outcomes of the multicentre, randomised HOST-IDEA trialJung-Kyu Han, Doyeon Hwang, Seokhun Yang, et al.
Circulation|March 5, 2023
Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical TrialJung-Kyu Han, Doyeon Hwang, Seokhun Yang, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 30, 2023
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trialKyu-Sun Lee, Keun-Ho Park, Kyung Woo Park, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 25, 2023
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertensionKi-Chul Sung, Soon Jun Hong, Moo-Yong Rhee, et al.
Pageof 7